Biomedical subjects

M Y Im

Publications and source records attributed to M Y Im.

2 recordsLinked to original sources

PubMed2000

The p53 mutation which abrogates trans-activation while maintaining its growth-suppression activity.

The p53 tumor suppressor protein functions as a transcription factor. It has, however, been previously reported that some p53 mutants are able to suppress cell growth independent of their transcriptional activity [Kaneuchi et al., (1999)]. In order to investigate the correlations between the trans-activation and growth-suppressive functions of p53, we have analyzed five p53 mutants by CAT reporter assay, colony formation assay, and growth-rate analysis. Five p53 mutants [Oh et al., (2000)]--199stop (Gly-->stop), 240ile (Ser-->Ile), 250ala (Pro-->Ala), 285lys (Glu-->Lys), and 291asn (Lys-->Asn)--were cotransfected with a reporter construct containing a p53-responsive element and then tested for their trans-activational activity in p53-null Saos-2 cells. As a result of a change in the protein structure, trans-activational activity was negated in 199stop, 240ile, 285lys, and 291asn, while 250ala retained its activity. Colony formation assay revealed that mutants 240ile and 250ala retained their growth suppression, while 199stop, 285lys, and 291asn did not. To study the features of these proteins, a group of isogenic cell lines that express mutant forms of p53 was generated from HeLa cells, and their growth rate was then examined: one group, containing 199stop, 285lys, and 291asn, showed a rapid growth rate, similar to that of the original HeLa cells; the other group, containing 240ile and 250ala, however, exhibited a slow growth rate. In conclusion, mutant p53 240ile, which completely lost its trans-activational activity, nevertheless continued to exhibit its growth-suppressive activity. Further work is required to understand how 240ile is involved in growth suppression.

Apoptosis↗

PubMed2000

Identification of p53 gene mutations in breast cancers and their effects on transcriptional activation function.

Somatic mutations in the p53 tumor suppressor gene are the most common genetic alterations found in human malignancies. In the present study, we studied 36 primary human breast carcinomas, using a polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and sequencing analysis of exons 2 through 9 for the presence of p53 gene mutations. Six of 36 (17%) breast cancers contained mutations within the core domain of the p53 protein responsible for sequence-specific DNA binding (codons 102-292); all 5 missense mutations clustered between codons 240 and 291 (codons 240, 243, 250, 285, and 291), whereas one nonsense mutation occurred at codon 199. By using recombinant PCR in vitro mutagenesis, we introduced point mutations at codons 199 from Gly to stop (gly199stop), 240 from Ser to Ile (ser240Ile), 250 from Pro to Ala (pro250ala), 285 from Glu to Lys (glu285lys), and 291 from Lys to Asn (lys291asn), and all the p53 sequences were subcloned into the CMVneoBam vector under the control of the cytomegalovirus (CMV) promoter. To test whether the mutants p53 were functionally wild-type (wt) or mutant, we transfected them to p53-null Saos-2 cells with a reporter plasmid containing a p53-responsive element, and performed chloramphenicol acetyltransferase (CAT) assay. Transient CAT assay for transcriptional activation revealed that one group, including gly199stop, ser240ile, glu285lys, and lys291asn, abolished the transcriptional activity, whereas the other group, including pro250ala, retained stronger transcriptional transactivation activity than that of wt p53.

Adult↗